Indications and treatment scope of related diseases of icorituzumab

Epcoritumab (Epcoritamab) is an innovative immunotherapy drug that is a bispecific T cell engaging antibody. It mainly targets CD20-positive B cells and the CD3 receptor on the surface of T cells, guiding T cells to the vicinity of tumor cells, thereby activating T cells to produce a cytotoxic response and achieving the elimination of B cell malignant tumors. Epcoritamab has been approved for the treatment of multiple types of B cell-derived non-Hodgkin lymphoma and is one of the drugs that has attracted much attention in the field of immuno-oncology treatment in recent years.

In terms of specific indications,Epcoritamab is mainly used for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This is a highly aggressive type of non-Hodgkin lymphoma. Although traditional treatments such as R-CHOP can be used as first-line treatment, a considerable proportion of patients will still experience recurrence or drug resistance after treatment, and there is a lack of effective follow-up treatment options. Epcoritamab provides a new immunotherapy option for these patients and is suitable for adult patients whose disease is still difficult to control after receiving two or more lines of systemic treatment, especially those who have insufficient response or intolerance to other therapies.

In addition toDLBCL, Epcoritamab has also been expanded to the treatment of high-grade B-cell lymphoma (HGBCL). This type of lymphoma has a higher proliferation index and genetic complexity, rapid disease progression, and a relatively poor prognosis. Epcoritamab directly activates T cells to kill tumor cells, providing an alternative to chemotherapy for the treatment of HGBCL, and is especially suitable for immune reconstruction after failure of multiple lines of treatment.

At the same time, the drug is also suitable for patients with relapsed or refractory follicular lymphoma (FL). FL is an indolent B-cell lymphoma, but even in the slowly progressive stages of the disease, it often relapses and develops into more aggressive forms. The application goal of Epcoritamab in such patients is to improve the response rate and prolong progression-free survival. Especially when traditional immunochemotherapy is ineffective, its strong targeting and immunomodulatory advantages are particularly prominent.

Reference materials:https://www.drugs.com/epcoritamab.html